Company Mission & Profile

22nd Century is a plant biotechnology company with an important mission: To Reduce the Harm Caused by Smoking.

Our proprietary genetic engineering technology and plant breeding expertise allow us to regulate the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result of our unique technology, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as plants with relatively high nicotine levels. The applications for this technology are extraordinary; in independent clinical studies, our Very Low Nicotine Content (VLNC) cigarettes have demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.

We have an extensive intellectual property portfolio of issued patents and patent applications relating to the tobacco and cannabis/hemp plants.

Goodrich Tobacco Company, LLC, Botanical Genetics, NASCO Products, LLC, and Heracles Pharmaceuticals, LLC are wholly-owned subsidiaries of 22nd Century Group.

2018 Annual Report

Download 2018 Annual Report (PDF)

The U.S. Food and Drug Administration published in the Federal Register the Agency’s Advance Notice of Proposed Rulemaking (ANPRM) to lower nicotine in cigarettes to minimally or non-addictive levels.  With ownership or control of patents on the genes in the tobacco plant that regulate nicotine production, 22nd Century is able to grow tobacco with up to 97% less nicotine than tobacco used in conventional cigarettes.

In commenting on the ANPRM, FDA Commissioner Dr. Scott Gottlieb said, “This milestone places us squarely on the road toward achieving one of the biggest public health victories in modern history and saving millions of lives in the process.”

22nd Century Responds to the FDA’s Nicotine Reduction Plan

The full text of the Company’s response to the FDA is available at:


Advisory note: global nicotine reduction strategy

WHO Study Group on Tobacco Product Regulation


This advisory note presents the conclusions and recommendations of the members of the WHO Study Group on Tobacco Product Regulation (TobReg) on a policy for limiting the sale of cigarettes to brands with a nicotine content that is not sufficient to lead to the development and/or maintenance of addiction.

SOURCE: WHO Global Nicotine Reduction Strategy


Landmark Study on Very Low Nicotine Cigarettes

Randomized Trial of Reduced-Nicotine Standards for Cigarettes
– Eric C. Donny, Ph.D., et. al.
Randomized Trial of Reduced-Nicotine Standards for Cigarettes (Key Points Video)
– Eric C. Donny, Ph.D., et. al.

Reduced-Nicotine Cigarettes — A Promising Regulatory Pathway
– Michael Fiore, M.D., M.P.H., M.B.A., and Timothy Baker, Ph.D.